Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
813 Leser
Artikel bewerten:
(2)

Gummi World Makes History: First U.S. Gummy Manufacturer to Earn Over-the-Counter Drug Certification

Breakthrough OTC 455-4 Certification Positions Gummi World as the First Pharmaceutical-Grade Gummy Partner in the U.S.

CHANDLER, AZ / ACCESS Newswire / June 12, 2025 / Gummi World, a wholly owned subsidiary of Intiva Group and an industry leader in custom supplement manufacturing, has achieved a historic milestone, becoming the first gummy manufacturer in the United States to receive OTC 455-4 certification. This officially designates the company as a compliant manufacturer of over-the-counter (OTC) drug products in gummy form, bridging the gap between consumer-friendly formats and pharmaceutical-grade production standards. Gummi World now has the authority to formulate, produce, and package FDA-compliant OTC medications in gummy form.

"With this OTC certification, Gummi World is changing what's possible for gummy manufacturing," said Alexander C. Candelario, Chairman and CEO of Intiva Group, Gummi World's parent company. "Being the first U.S. gummy manufacturer to receive OTC certification reaffirms our dedication to innovation, quality, and regulatory excellence. Our partners now have access to a manufacturing platform that combines clinical-grade precision with unmatched speed to market."

A First in the Gummy Industry

OTC 455-4 is one of the toughest certifications in the U.S., usually limited to pharmaceutical companies making pills or liquids. Gummi World's OTC certification breaks that mold, proving that gummies can now be a credible, FDA-compliant way to deliver OTC medications.

This distinction authorizes Gummi World to manufacture and package pharmacy-grade OTC medications in gummy form, including:

  • Pain relievers (acetaminophen, ibuprofen)

  • Cold and flu symptom relievers

  • Sleep aids

  • Antihistamines

For retailers and product developers, this opens new opportunities: delivering effective medications in formats consumers prefer without compromising compliance or efficacy.

One Roof. Total Compliance.

This achievement is backed by Gummi World's FDA-registered, vertically integrated facility in Chandler, Arizona. With formulation, manufacturing, packaging, and quality control under one roof, every step is tightly controlled, providing clients with full traceability, rapid turnaround, and airtight compliance from concept to shelf.

Gummi World's infrastructure now supports:

  • OTC-compliant production with validated tracking and documentation

  • In-house stability, microbial, and heavy metal testing

  • Scalable operations for pilot runs or national distribution

  • Capsule manufacturing for powders, semi-solids, and select liquids

Why This Matters to Brands & Retailers

For Gummi World's clients, from global wellness brands to startups, this certification means:

  • Access to true OTC products in gummy form, made under FDA oversight

  • A trusted, turnkey partner ready to handle compliance from day one

  • Speed-to-shelf solutions without compromising safety, flavor, or efficacy

  • Pharmaceutical credibility that meets the standards of major retailers

"By becoming OTC certified, we're helping our clients expand into new product categories that were previously out of reach for gummies," said Candelario. "We're proud to help them be first to market, not just compliant."

Setting a New Standard for the Industry

While many manufacturers are still catching up, Gummi World is setting the pace by bringing pharma-level standards to the consumer health space. This OTC certification marks the first of several expansions planned for 2025 as the company evolves into a full-scale pharmaceutical-grade contract partner, positioned to lead the market in next-generation gummy drug delivery. From national retailers to global nutraceutical brands and pharmaceutical innovators, Gummi World is ready to deliver. Learn more or request a quote at www.gummiworld.com.

Contact Information

Claudia Giunta
Content Lead
claudia@intivahealth.com

.

SOURCE: Gummi World



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/gummi-world-makes-history-first-u.s.-gummy-manufacturer-to-earn-over-1038818

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.